Bendandi Maurizio
Center for Applied Medical Research, University of Navarra, 31008 Pamplona, Spain.
Nat Rev Cancer. 2009 Sep;9(9):675-81. doi: 10.1038/nrc2717.
The clonal immunoglobulin idiotype displayed on the surface of most malignant B cells is a patient- and tumour-specific antigen that can be used for therapeutic vaccination. Several studies have confirmed the biological efficacy of soluble protein idiotypic vaccination and two clinical trials have shown the clinical efficacy of this procedure. One study has demonstrated clinical benefit associated with idiotypic vaccination. However, three randomized clinical trials have recently failed to achieve their main end points for reasons that are probably unrelated to the vaccine. While scepticism towards this type of non-toxic medical intervention is mounting, such patient-specific treatments might yet see the light of day through better designed clinical trials.
大多数恶性B细胞表面显示的克隆免疫球蛋白独特型是一种患者和肿瘤特异性抗原，可用于治疗性疫苗接种。多项研究证实了可溶性蛋白独特型疫苗接种的生物学疗效，两项临床试验显示了该程序的临床疗效。一项研究证明了与独特型疫苗接种相关的临床益处。然而，最近三项随机临床试验未能达到其主要终点，原因可能与疫苗无关。尽管对这种无毒医学干预的怀疑情绪日益增加，但通过设计更完善的临床试验，这种针对患者的治疗方法可能仍会迎来曙光。
